Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide

2 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide
Treatment and conditionWhere it standsTrials
Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1